A phase II trial of sorafenib in first-line metastatic urothelial cancer: A study of the PMH Phase II Consortium

Investigational New Drugs

Volumn 29, Issue 5, 2011, Pages 1045-1049

  Sridhar, Srikala S ^a   Winquist, Eric ^b   Eisen, Andrea ^c   Hotte, Sebastien J ^d   McWhirter, Elaine ^d   Tannock, Ian F ^a   Mukherjee, Som D ^d   Wang, Lisa ^a   Blattler, Chantale ^a   Wright, John J ^e   Moore, Malcolm J ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b LONDON REGIONAL CANCER PROGRAM   (Canada)

^c DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^d JURAVINSKI CANCER CENTRE   (Canada)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

First line; Metastatic urothelial cancer; Phase II; Sorafenib

Indexed keywords

SORAFENIB; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACKACHE; BLADDER CANCER; BLADDER INFECTION; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CONSTIPATION; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FUNCTIONAL STATUS; HAND FOOT SYNDROME; HUMAN; JEJUNUM DISEASE; JEJUNUM PERFORATION; KIDNEY PELVIS CANCER; MALE; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA; TREATMENT DURATION; TREATMENT RESPONSE; URETER CANCER; URINARY TRACT INFECTION; CLINICAL TRIAL; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME; URINARY TRACT CANCER; UROTHELIUM;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROTEIN KINASE INHIBITORS; PYRIDINES; TREATMENT OUTCOME; UROLOGIC NEOPLASMS; UROTHELIUM;

EID: 84856071311     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9408-4     Document Type: Article

References (25)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M (2001) Cancer statistics, 2001. CA Cancer J Clin 51:15-36
2. von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, Kerbrat P, Sanchez Rovira P, Wersall P, Cleall SP, Roychowdhury DF, Tomlin I, Visseren-Grul CM, Conte PF (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18:3068-3077
3. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099-7109
4. Sridhar SS, Hedley D, Siu LL (2005) Raf kinase as a target for anticancer therapeutics. Mol Cancer Ther 4:677-685
5. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134
6. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB (2006) Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24:4293-4300
7. McDermott DF, Sosman JA, Gonzalez R, Hodi FS, Linette GP, Richards J, Jakub JW, Beeram M, Tarantolo S, Agarwala S, Frenette G, Puzanov I, Cranmer L, Lewis K, Kirkwood J, White JM, Xia C, Patel K, Hersh E (2008) Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol 26:2178-2185
8. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390
9. Vageli D, Kiaris H, Delakas D, Anezinis P, Cranidis A, Spandidos DA (1996) Transcriptional activation of H-ras, K-ras and N-ras proto-oncogenes in human bladder tumors. Cancer Lett 107:241-247
10. Viola MV, Fromowitz F, Oravez S, Deb S, Schlom J (1985) ras Oncogene p21 expression is increased in premalignant lesions and high grade bladder carcinoma. J Exp Med 161:1213-1218
11. Oxford G, Theodorescu D (2003) The role of Ras superfamily proteins in bladder cancer progression. J Urol 170:1987-1993
12. Simon R, Richter J, Wagner U, Fijan A, Bruderer J, Schmid U, Ackermann D, Maurer R, Alund G, Knonagel H, Rist M, Wilber K, Anabitarte M, Hering F, Hardmeier T, Schonenberger A, Flury R, Jager P, Fehr JL, Schraml P, Moch H, Mihatsch MJ, Gasser T, Sauter G (2001) High-throughput tissue microarray analysis of 3p25 (RAF1) and 8p12 (FGFR1) copy number alterations in urinary bladder cancer. Cancer Res 61:4514-4519
13. Bue P, Wester K, Sjostrom A, Holmberg A, Nilsson S, Carlsson J, Westlin JE, Busch C, Malmstrom PU (1998) Expression of epidermal growth factor receptor in urinary bladder cancer metastases. Int J Cancer 76:189-193
14. Crew JP, O'Brien T, Bradburn M, Fuggle S, Bicknell R, Cranston D, Harris AL (1997) Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res 57:5281-5285
15. O'Brien T, Cranston D, Fuggle S, Bicknell R, Harris AL (1995) Different angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Res 55:510-513
16. Sonpavde G, Jian W, Liu H, Wu MF, Shen SS, Lerner SP (2009) Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model. Urol Oncol 27:391-399
17. Wu W, Shu X, Hovsepyan H, Mosteller RD, Broek D (2003) VEGF receptor expression and signaling in human bladder tumors. Oncogene 22:3361-3370
18. Duff SE, Jeziorska M, Rosa DD, Kumar S, Haboubi N, Sherlock D, O'Dwyer ST, Jayson GC (2006) Vascular endothelial growth factors and receptors in colorectal cancer: implications for antiangiogenic therapy. Eur J Cancer 42:112-117
19. Moore MJ, Tannock IF, Ernst DS, Huan S, Murray N (1997) Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 15:3441-3445
20. Stadler WM, Kuzel T, Roth B, Raghavan D, Dorr FA (1997) Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 15:3394-3398
21. Bajorin DF, Dodd PM, Mazumdar M, Fazzari M, McCaffrey JA, Scher HI, Herr H, Higgins G, Boyle MG (1999) Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 17:3173-3181
22. Dreicer R, Li H, Stein M, DiPaola R, Eleff M, Roth BJ, Wilding G (2009) Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group. Cancer 115:4090-4095
23. Bellmunt J, Maroto P, Mellado B, Carles J, Calvo E, Alcaraz A, Placer J, Villaviciencio H, Grande E, Albanell J (2008) Phase II study of sunitinib as first line treatment in patients with advanced urothelial cancer ineligible for cisplatin-based chemotherapy. In: Genitourinary Cancers Symposium. Abstract 291.
24. Gallagher D, Milowsky M, Gerst S, Tickoo S, Ishill N, Regazzi A, Trout A, Bajorin D (2009) A phase II study of sunitinib on a continuous dosing schedule in patients (pts) with relapsed or refractory urothelial carcinoma (UC). In: ASCO Annual Meeting. Journal of Clinical Oncology, Orlando, FL, Abstract 5072.
25. Hussain MH, MacVicar GR, Petrylak DP, Dunn RL, Vaishampayan U, Lara PN Jr, Chatta GS, Nanus DM, Glode LM, Trump DL, Chen H, Smith DC (2007) Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol 25:2218-2224